151 related articles for article (PubMed ID: 2101728)
1. Neuroblastoma: clinical significance of genetic abnormalities.
Brodeur GM
Cancer Surv; 1990; 9(4):673-88. PubMed ID: 2101728
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma--clinical applications of molecular parameters.
Brodeur GM
Brain Pathol; 1990 Sep; 1(1):47-54. PubMed ID: 1669693
[TBL] [Abstract][Full Text] [Related]
3. Neuroblastoma. Effect of genetic factors on prognosis and treatment.
Brodeur GM; Azar C; Brother M; Hiemstra J; Kaufman B; Marshall H; Moley J; Nakagawara A; Saylors R; Scavarda N
Cancer; 1992 Sep; 70(6 Suppl):1685-94. PubMed ID: 1325279
[TBL] [Abstract][Full Text] [Related]
4. Significance of chromosome 1p loss of heterozygosity in neuroblastoma.
Maris JM; White PS; Beltinger CP; Sulman EP; Castleberry RP; Shuster JJ; Look AT; Brodeur GM
Cancer Res; 1995 Oct; 55(20):4664-9. PubMed ID: 7553646
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas.
Fong CT; White PS; Peterson K; Sapienza C; Cavenee WK; Kern SE; Vogelstein B; Cantor AB; Look AT; Brodeur GM
Cancer Res; 1992 Apr; 52(7):1780-5. PubMed ID: 1551108
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of clinical heterogeneity in neuroblastoma.
Brodeur GM; Nakagawara A
Am J Pediatr Hematol Oncol; 1992 May; 14(2):111-6. PubMed ID: 1356315
[TBL] [Abstract][Full Text] [Related]
7. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
Martinsson T; Sjöberg RM; Hedborg F; Kogner P
Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
[TBL] [Abstract][Full Text] [Related]
8. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
[TBL] [Abstract][Full Text] [Related]
9. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma.
Gehring M; Berthold F; Edler L; Schwab M; Amler LC
Cancer Res; 1995 Nov; 55(22):5366-9. PubMed ID: 7585602
[TBL] [Abstract][Full Text] [Related]
10. Clinical investigation of neuroblastoma with partial deletion in the short arm of chromosome 1.
Ohtsu K; Hiyama E; Ichikawa T; Matsuura Y; Yokoyama T
Clin Cancer Res; 1997 Jul; 3(7):1221-8. PubMed ID: 9815803
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetic features of human neuroblastomas and cell lines.
Brodeur GM; Green AA; Hayes FA; Williams KJ; Williams DL; Tsiatis AA
Cancer Res; 1981 Nov; 41(11 Pt 1):4678-86. PubMed ID: 6171342
[TBL] [Abstract][Full Text] [Related]
12. Different karyotypic patterns in early and advanced stage neuroblastomas.
Kaneko Y; Kanda N; Maseki N; Sakurai M; Tsuchida Y; Takeda T; Okabe I; Sakurai M
Cancer Res; 1987 Jan; 47(1):311-8. PubMed ID: 3791218
[TBL] [Abstract][Full Text] [Related]
13. Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.1.
Spieker N; Beitsma M; Van Sluis P; Chan A; Caron H; Versteeg R
Genes Chromosomes Cancer; 2001 Jun; 31(2):172-81. PubMed ID: 11319804
[TBL] [Abstract][Full Text] [Related]
14. Genetic alterations involving chromosome 1p in children with neuroblastoma.
Avigad S; Tamir Y; Yaniv I; Goshen J; Kaplinsky C; Cohen IJ; Zaizov R
Isr J Med Sci; 1994 Aug; 30(8):639-41. PubMed ID: 7913920
[TBL] [Abstract][Full Text] [Related]
15. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study.
Cohn SL; Look AT; Joshi VV; Holbrook T; Salwen H; Chagnovich D; Chesler L; Rowe ST; Valentine MB; Komuro H
Cancer Res; 1995 Feb; 55(4):721-6. PubMed ID: 7850780
[TBL] [Abstract][Full Text] [Related]
16. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma.
Ambros IM; Zellner A; Roald B; Amann G; Ladenstein R; Printz D; Gadner H; Ambros PF
N Engl J Med; 1996 Jun; 334(23):1505-11. PubMed ID: 8618605
[TBL] [Abstract][Full Text] [Related]
17. Analysis of genomic imprinting at 1p35-36 in neuroblastoma.
Hogarty MD; Maris JM; White PS; Guo C; Brodeur GM
Med Pediatr Oncol; 2001 Jan; 36(1):52-5. PubMed ID: 11464906
[TBL] [Abstract][Full Text] [Related]
18. Intratumoural heterogeneity of 1p deletions and MYCN amplification in neuroblastomas.
Ambros PF; Ambros IM; Kerbl R; Luegmayr A; Rumpler S; Ladenstein R; Amann G; Kovar H; Horcher E; De Bernardi B; Michon J; Gadner H
Med Pediatr Oncol; 2001 Jan; 36(1):1-4. PubMed ID: 11464855
[TBL] [Abstract][Full Text] [Related]
19. [Amplification of N-myc in neuroblastoma: paradigm for clinical use of an oncogene alteration].
Schwab M
Klin Padiatr; 1990; 202(4):197-201. PubMed ID: 2203936
[TBL] [Abstract][Full Text] [Related]
20. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease.
Mora J; Cheung NK; Chen L; Qin J; Gerald W
Cancer; 2001 Jan; 91(2):435-42. PubMed ID: 11180092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
